

**Meeting Notes: Interagency Meeting (FDA, EPA, CDC, NIH, BARDA) with Oxitec/Intrexon  
May 17, 2017**

**Overview**

# **Ex. 5 - Deliberative Process**

[PAGE \ MERGEFORMAT]

## **Ex. 5 - Deliberative Process**

EPA, FDA and Oxitec discussed paths forward, given the regulatory options:

## **Ex. 5 - Deliberative Process**

Post-meeting Notes: Next Steps per Oxitec/Intrexon from the company's feedback on Mon May 22:

## **Ex. 5 - Deliberative Process**